PDA Technical Report No. 79 (TR 79) Particulate Matter Control in Difficult to Inspect Parenterals (single user digital version)
Premium Members: to claim your annual free technical document download, email membership@pda.org and indicate the document you wish to claim.
- Format
- PDF Single user
- Member Price
- $180.00
- Nonmember Price
- $325.00
- Government Price
- $180.00
Please sign in or become a member to purchase items from the PDA bookstore.
PDA Technical Report No. 79, Particulate Matter Control in Difficult to Inspect Parenterals describes best practices for difficult to inspect parenteral (DIP) product lifecycle management, destructive testing, and trending to supplement portions of the guidance given in USP General Chapter<1790>: Visible Particulates in Injection.
In 2015, the PDA Task Force on Particulate Matter Control in Difficult to Inspect Parenterals initiated an industry survey on DIP products. literature, pharmacopeial references, and the collective expertise of Task Force contributors form the basis for the information provided in this technical report.
This Technical Report is intended to provide logical pathways to DIP product inspection and testing to support continual process improvement in the industry.
Available to download. Prior to purchase please view the download instructions and Terms of Usage.
Format: PDF (1 file 1.05 MB)
Click here to order paper ship version (Item no. 01079).
*To purchase licensing, please contact PDA at info@pda.org.
Table of Contents
Table of Contents:
Click here to download >>> Detailed Table of Contents- Introduction
- Glossary
- Overview
- Expectations for DIP Inspection
- Inspection Approaches for DIP Products/Containers/Devices
- Defect Prevention: A Lifecycle Approach
- Conclusion
- References
- Appendix 1: Enhanced Methods for Revealing Visible Particles
Figures and Tables Index
About the Authors
Roy Cherris, Bridge Associates International- InQuest Science, Co-Chair
Ulrich Valley, PhD, Novartis, Co-Chair
Lars Aabye-Hansen, Novo Nordisk
Roy McLean, Baxter
Dirk Overroedder, PhD, Johnson and Johnson
Amy Owen, Hospira, a Pfizer Company
John Shabushnig, PhD, Insight Pharma Consulting, LLC
Scott Aldrich, Ultramikro LLC
Romain Veillon, GSK Vaccines
Rick Watson, Merck Sharp & Dohme Corp.